1WILSON TANG W H, FRANCIS G S. The year in heart failure[J]. J Am Coll Cardiol, 2007,50:2344- 2351.
2KUBO T, GIMENO J R, BAHL A, et al. Prevalence, clinical significance, and genetic basic of hypertrophic cardiomyopathy[J]. J Am Coll Cardiol, 2007, 49:2419-2426.
3SEN-CHOWDHRY S, SYRRIS P, WARD D, et al. Clinical and genetic characterization of families with arrhythmogenic right ventricular dysplasis/cardiomyopathy provides novel insights into patterns of disease expression[J]. Circulation, 2007,115 : 1710-1720.
4FATKIN D. Guidelines for the diagnosis and management of hypertrophic cardiomyopathy[J]. Heart Lung Circ,2007,16:19-21.
5METRA M, NODARI S, PARRINELLO G, et al. The role of plasma biomarker measurements in acute heart failure. Serial changes and independent prognostic value of NT-proBNP and troponin T[J]. Eur J Heart Fail, 2007,9:776-786.
6MILLER W L, HARTMAN K A, BURRITT M F, et al. Serial biamarker measurements in ambulatory patients with chronic heart failure; the importance of change over time[J]. Circulation, 2007, 115:249 - 257.
7CLELANT J G, COLETTTA A P, CLARK A L. Clinical trials update from American College of Cardiology 2007: ALPHA, EVEREST, FUSIONII, VALIDD, PARR-2, REMODEL, SPICE, COURAGE, COACH, REMADHE, pro-BNP for the evaluation of dyspnoea and THIS-diet[J]. Eur J Heart Fail, 2007,9:740-745.
8VOLLMANN D, NAGELE H, SCHAUERTE P, et al. Clincal utility of intrathoracic impedance monitoring to alert patients with implant device of deteriorating chronic heart failure[J]. Eur Heart J,2007,28:1835-1840.
9CLELAND J G, ABDELLAH A T, KHALEVA O, et al. Clinical trials update from the European Society of Cardiology Congress 2007 : 3CPO, ALOFT, PROSPECT and statins for heart failure[J]. Eur J Heart Fail, 2007, 9:1070-1073.
10LAM C S,ROGER V L, RODEHEFFER R J, et al. Cardiac structure and ventricular function in persons with heart failure and preserved ejection fraction from Olmsted County, Minnesota [J]. Circulation, 2007, 115:1982-1990.
6PITT B,ZANNAD F,REMME W J,et al.The effect of spironolactone on morbidity and mortality in patients with severe heart failure[J].N Engl J Med,1999,341:709-717.
7PITT B,REMME W,ZANNAD F,et al.Eperenone,a selective aldosterone blocker in patient with left ventricular dysfunction after myocardial infarction[J].N Engl J Med,2003,348:1309-1321.
8REDFIELD M M,JACOBSEN S J,BURNETT J C,et al.Burden of systolic and diastolic ventricular dysfunction in the community:appreciating the scope of the heart failure epidemic[J].JAMA,2003,289:194-202.
9BRAUNWALD E,BRISTOW M R.Congestive heart failure:fifty years of progress[J].Circulation,2000,102:IV-14-23.
10The SOLVD Investigators.Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions published erratum appears in[J].N Engl J Med,1992,327:685-691.
